Advances in ovarian cancer therapy
Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free perio...
Uloženo v:
| Vydáno v: | Cancer chemotherapy and pharmacology Ročník 81; číslo 1; s. 17 - 38 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.01.2018
Springer Nature B.V |
| Témata: | |
| ISSN: | 0344-5704, 1432-0843, 1432-0843 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free periods and recurrence episodes. Different targeted treatment approaches and biological drugs, currently under development, bring the promise of turning ovarian cancer into a manageable chronic disease. In this review, we discuss the current standard in the therapy for ovarian cancer, major recent studies on the new variants of conventional therapies, and new therapeutic approaches, recently approved and/or in clinical trials. The latter include anti-angiogenic therapies, polyADP-ribose polymerase (PARP) inhibitors, inhibitors of growth factor signaling, or folate receptor inhibitors, as well as several immunotherapeutic approaches. We also discuss cost-effectiveness of some novel therapies and the issue of better selection of patients for personalized treatment. |
|---|---|
| AbstractList | Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free periods and recurrence episodes. Different targeted treatment approaches and biological drugs, currently under development, bring the promise of turning ovarian cancer into a manageable chronic disease. In this review, we discuss the current standard in the therapy for ovarian cancer, major recent studies on the new variants of conventional therapies, and new therapeutic approaches, recently approved and/or in clinical trials. The latter include anti-angiogenic therapies, polyADP-ribose polymerase (PARP) inhibitors, inhibitors of growth factor signaling, or folate receptor inhibitors, as well as several immunotherapeutic approaches. We also discuss cost-effectiveness of some novel therapies and the issue of better selection of patients for personalized treatment. Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free periods and recurrence episodes. Different targeted treatment approaches and biological drugs, currently under development, bring the promise of turning ovarian cancer into a manageable chronic disease. In this review, we discuss the current standard in the therapy for ovarian cancer, major recent studies on the new variants of conventional therapies, and new therapeutic approaches, recently approved and/or in clinical trials. The latter include anti-angiogenic therapies, polyADP-ribose polymerase (PARP) inhibitors, inhibitors of growth factor signaling, or folate receptor inhibitors, as well as several immunotherapeutic approaches. We also discuss cost-effectiveness of some novel therapies and the issue of better selection of patients for personalized treatment.Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free periods and recurrence episodes. Different targeted treatment approaches and biological drugs, currently under development, bring the promise of turning ovarian cancer into a manageable chronic disease. In this review, we discuss the current standard in the therapy for ovarian cancer, major recent studies on the new variants of conventional therapies, and new therapeutic approaches, recently approved and/or in clinical trials. The latter include anti-angiogenic therapies, polyADP-ribose polymerase (PARP) inhibitors, inhibitors of growth factor signaling, or folate receptor inhibitors, as well as several immunotherapeutic approaches. We also discuss cost-effectiveness of some novel therapies and the issue of better selection of patients for personalized treatment. |
| Author | Tudrej, Patrycja Kujawa, Katarzyna A. Cortez, Alexander J. Lisowska, Katarzyna M. |
| Author_xml | – sequence: 1 givenname: Alexander J. surname: Cortez fullname: Cortez, Alexander J. organization: Maria Skłodowska-Curie Institute - Oncology Center, Gliwice Branch – sequence: 2 givenname: Patrycja surname: Tudrej fullname: Tudrej, Patrycja organization: Maria Skłodowska-Curie Institute - Oncology Center, Gliwice Branch – sequence: 3 givenname: Katarzyna A. surname: Kujawa fullname: Kujawa, Katarzyna A. organization: Maria Skłodowska-Curie Institute - Oncology Center, Gliwice Branch – sequence: 4 givenname: Katarzyna M. orcidid: 0000-0001-9786-3993 surname: Lisowska fullname: Lisowska, Katarzyna M. email: katarzyna.lisowska@io.gliwice.pl organization: Maria Skłodowska-Curie Institute - Oncology Center, Gliwice Branch |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29249039$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUtrHDEQhEWwiddOfkAuYUkuuUzcrbcuAWPyAoMvzlnI2h5bZlbaSLML_veZYR3jGJKcBNJX1aWuY3aQSybG3iB8RABz2gC4hQ7QdEIBdvYFW6AUvAMrxQFbgJCyUwbkETtu7Q4AJArxkh1xx6UD4Rbs3dlqF3Kktkx5WXahppCXcb6py_GWatjcv2KHfRgavX44T9iPL5-vzr91F5dfv5-fXXRRgRg77A1oY4MhtEpyR6iEVmYFipy0YUXaaWs0XUfZy0BOo6M-aoPcYQjGiRP2ae-72V6vaRUpjzUMflPTOtR7X0Lyf77kdOtvys4ro6REmAw-PBjU8nNLbfTr1CINQ8hUts0LDppzjpb_F0Vn7IQbbSf0_TP0rmxrnjYxU0ajUU5M1Nun4R9T_970BOAeiLW0Vql_RBD83Kbft-mnNv3cpp9Hm2eamMYwpjL_Pw3_VPK9sk1T8g3VJ6H_KvoFx7-wBQ |
| CitedBy_id | crossref_primary_10_1002_cbf_3549 crossref_primary_10_1016_j_bbcan_2020_188446 crossref_primary_10_1038_s41598_021_93992_1 crossref_primary_10_1210_endocr_bqae110 crossref_primary_10_3390_cancers16010107 crossref_primary_10_1186_s12885_018_5250_4 crossref_primary_10_1002_smll_202100287 crossref_primary_10_3389_fmolb_2024_1520876 crossref_primary_10_1002_jcb_29431 crossref_primary_10_3390_biomedicines10092113 crossref_primary_10_1007_s10151_018_1849_3 crossref_primary_10_1016_j_ebiom_2019_11_009 crossref_primary_10_3389_fgene_2022_886170 crossref_primary_10_3390_ijms22126532 crossref_primary_10_1038_s41417_019_0156_0 crossref_primary_10_1093_jnci_djz217 crossref_primary_10_3390_jpm13071045 crossref_primary_10_1016_j_gene_2020_145224 crossref_primary_10_1002_adhm_202200356 crossref_primary_10_1186_s12885_022_09699_7 crossref_primary_10_1111_bcpt_13487 crossref_primary_10_3390_cancers13081839 crossref_primary_10_1016_j_biopha_2024_116296 crossref_primary_10_1002_ange_202117330 crossref_primary_10_1177_0300060520976824 crossref_primary_10_1016_j_biochi_2022_09_005 crossref_primary_10_1038_s41598_024_62568_0 crossref_primary_10_3390_biomedicines10020199 crossref_primary_10_3390_cancers14246246 crossref_primary_10_1016_j_ejca_2022_11_033 crossref_primary_10_3892_etm_2023_12303 crossref_primary_10_1177_1078155218800156 crossref_primary_10_1038_s41540_024_00418_5 crossref_primary_10_1007_s13404_023_00339_x crossref_primary_10_1016_j_prp_2018_10_025 crossref_primary_10_1016_j_prp_2025_155983 crossref_primary_10_1136_jitc_2021_003645 crossref_primary_10_1186_s12935_019_1062_0 crossref_primary_10_1155_2022_5887671 crossref_primary_10_1088_2053_1591_ac5077 crossref_primary_10_1016_j_canlet_2019_07_002 crossref_primary_10_2147_OTT_S250850 crossref_primary_10_3390_biom15091241 crossref_primary_10_1016_j_yexcr_2020_112397 crossref_primary_10_3390_pharmaceutics10040245 crossref_primary_10_1021_acsbiomaterials_4c02060 crossref_primary_10_1186_s13000_023_01414_9 crossref_primary_10_3389_fonc_2022_936099 crossref_primary_10_1038_s41417_021_00400_x crossref_primary_10_3390_cancers12071713 crossref_primary_10_1016_j_matchemphys_2022_126560 crossref_primary_10_3390_jnt3020008 crossref_primary_10_1002_1878_0261_13076 crossref_primary_10_1016_j_prp_2024_155455 crossref_primary_10_21597_jist_1345204 crossref_primary_10_4155_fmc_2022_0244 crossref_primary_10_1038_s41598_025_11845_7 crossref_primary_10_1186_s13048_023_01262_7 crossref_primary_10_1002_cam4_2560 crossref_primary_10_1186_s12935_021_01953_5 crossref_primary_10_3390_cancers12041020 crossref_primary_10_1093_intimm_dxaa010 crossref_primary_10_1002_cmdc_201900450 crossref_primary_10_1080_01635581_2020_1801779 crossref_primary_10_1155_2019_3461251 crossref_primary_10_3233_CBM_230200 crossref_primary_10_3389_fonc_2022_1016958 crossref_primary_10_3390_cells11040641 crossref_primary_10_1002_advs_202201416 crossref_primary_10_3390_cancers11121887 crossref_primary_10_3390_cancers14071651 crossref_primary_10_1186_s13048_020_00629_4 crossref_primary_10_1530_EC_18_0425 crossref_primary_10_3390_cancers14010191 crossref_primary_10_3390_cancers13030493 crossref_primary_10_1016_j_bbcan_2021_188633 crossref_primary_10_1080_13548506_2019_1626452 crossref_primary_10_3389_fphar_2023_1147717 crossref_primary_10_1155_2022_3941630 crossref_primary_10_1177_15353702231151958 crossref_primary_10_1016_j_jelechem_2021_115854 crossref_primary_10_3389_fcell_2020_00758 crossref_primary_10_3390_ijms20204972 crossref_primary_10_1007_s13577_023_00962_y crossref_primary_10_1016_j_jconrel_2025_113890 crossref_primary_10_1038_s41597_022_01127_6 crossref_primary_10_3390_ijms242115862 crossref_primary_10_1186_s13048_019_0596_z crossref_primary_10_3892_mmr_2020_10979 crossref_primary_10_1007_s43032_024_01719_0 crossref_primary_10_3390_cancers16050959 crossref_primary_10_1016_j_colsurfb_2022_112766 crossref_primary_10_1007_s13273_024_00465_3 crossref_primary_10_4103_ijc_IJC_53_21 crossref_primary_10_1016_j_ebiom_2019_11_050 crossref_primary_10_1016_j_biopha_2023_115151 crossref_primary_10_1016_j_bpobgyn_2020_02_010 crossref_primary_10_1016_j_ejpb_2024_114526 crossref_primary_10_3390_molecules27217523 crossref_primary_10_1016_j_critrevonc_2023_104230 crossref_primary_10_1186_s13048_019_0588_z crossref_primary_10_1080_15384047_2025_2543105 crossref_primary_10_21802_artm_2024_2_30_95 crossref_primary_10_3389_fonc_2022_852260 crossref_primary_10_46879_ukroj_2_2024_216_230 crossref_primary_10_2147_IJN_S362263 crossref_primary_10_1016_j_bbcan_2020_188496 crossref_primary_10_32604_biocell_2024_047812 crossref_primary_10_12998_wjcc_v12_i11_1967 crossref_primary_10_1016_j_biopha_2025_118532 crossref_primary_10_1016_j_prp_2023_154697 crossref_primary_10_1002_ijc_34908 crossref_primary_10_1038_s41388_022_02181_5 crossref_primary_10_1016_j_fct_2025_115672 crossref_primary_10_1080_14796694_2024_2424153 crossref_primary_10_1007_s10616_021_00508_w crossref_primary_10_3390_cancers12082222 crossref_primary_10_1038_s41598_022_06585_x crossref_primary_10_1067_j_cpradiol_2024_08_009 crossref_primary_10_3390_ijms25063191 crossref_primary_10_1055_s_0041_1740323 crossref_primary_10_3390_cancers13184617 crossref_primary_10_1097_CCO_0000000000000661 crossref_primary_10_3389_fphar_2024_1496131 crossref_primary_10_2147_IJN_S272319 crossref_primary_10_1186_s13048_023_01284_1 crossref_primary_10_3390_molecules27196609 crossref_primary_10_1002_anie_202117330 crossref_primary_10_3390_cancers13225783 crossref_primary_10_3892_ol_2024_14624 crossref_primary_10_1016_j_ijbiomac_2025_145365 crossref_primary_10_1007_s12033_024_01215_5 crossref_primary_10_1016_j_ygyno_2019_12_020 crossref_primary_10_3390_ijms23031742 crossref_primary_10_3892_ol_2022_13585 crossref_primary_10_1186_s12920_020_00773_2 crossref_primary_10_3390_ijms23031868 crossref_primary_10_1080_01635581_2024_2383336 crossref_primary_10_1016_j_saa_2023_122411 crossref_primary_10_1186_s12943_023_01786_y crossref_primary_10_3389_fmed_2025_1573512 crossref_primary_10_3390_ijms241310960 crossref_primary_10_3390_ijms25031845 crossref_primary_10_3390_biomedicines9010055 crossref_primary_10_1097_COC_0000000000000830 crossref_primary_10_1038_s41388_021_01788_4 crossref_primary_10_1097_MD_0000000000042483 crossref_primary_10_1002_cbf_3607 crossref_primary_10_2147_IJN_S247114 crossref_primary_10_1007_s12195_024_00817_y crossref_primary_10_1021_acsomega_5c05260 crossref_primary_10_1002_jcb_27158 crossref_primary_10_3390_pharmaceutics12050401 crossref_primary_10_1016_j_mce_2023_112127 crossref_primary_10_1016_j_biopha_2018_07_059 crossref_primary_10_1016_j_arcmed_2020_09_001 crossref_primary_10_1021_acsami_5c02998 crossref_primary_10_1155_2022_4464056 crossref_primary_10_1093_intimm_dxz074 crossref_primary_10_1016_j_omton_2024_200864 crossref_primary_10_1155_2022_9398823 crossref_primary_10_3389_fonc_2022_1003512 crossref_primary_10_1039_C9RA03681D crossref_primary_10_1177_0284185119898654 crossref_primary_10_3390_ijms24087293 crossref_primary_10_1016_j_abb_2020_108565 crossref_primary_10_3390_ijms24032016 crossref_primary_10_1038_s41416_024_02677_9 crossref_primary_10_1186_s12935_020_01704_y crossref_primary_10_1136_jim_2020_001355 crossref_primary_10_1016_j_cclet_2024_110229 crossref_primary_10_1097_MD_0000000000019931 crossref_primary_10_1186_s13048_025_01712_4 crossref_primary_10_12688_f1000research_53364_1 crossref_primary_10_36469_jheor_2021_29145 crossref_primary_10_1007_s11095_022_03434_4 crossref_primary_10_1016_j_semcancer_2023_10_002 crossref_primary_10_3389_fonc_2021_655709 crossref_primary_10_2217_fon_2020_0083 crossref_primary_10_3390_cancers13102493 crossref_primary_10_1080_21655979_2021_1981795 crossref_primary_10_1186_s13048_024_01523_z crossref_primary_10_57264_cer_2023_0025 crossref_primary_10_1007_s00404_020_05545_y crossref_primary_10_3892_mmr_2022_12812 crossref_primary_10_4103_abr_abr_264_22 crossref_primary_10_1007_s00262_024_03674_w crossref_primary_10_1007_s00404_021_06070_2 crossref_primary_10_1038_s41598_024_74249_z crossref_primary_10_3389_fphar_2021_701487 crossref_primary_10_1007_s13402_023_00903_9 crossref_primary_10_1016_j_gene_2022_146275 crossref_primary_10_1155_2021_7103345 crossref_primary_10_1016_j_jconrel_2019_10_002 crossref_primary_10_3389_fcell_2021_690365 crossref_primary_10_1590_acb390524 crossref_primary_10_1016_j_lfs_2020_117296 crossref_primary_10_1186_s12885_019_6288_7 crossref_primary_10_3390_biomedicines13071525 crossref_primary_10_1016_j_heliyon_2025_e42188 crossref_primary_10_1159_000510098 crossref_primary_10_1177_09636897241281869 crossref_primary_10_1007_s00261_024_04542_y crossref_primary_10_1007_s00262_023_03529_w crossref_primary_10_1186_s12967_021_02781_x crossref_primary_10_3389_fonc_2023_1154073 crossref_primary_10_1016_j_fertnstert_2022_03_004 crossref_primary_10_3390_ijms22084091 crossref_primary_10_3390_cancers14235757 crossref_primary_10_1016_j_cpsurg_2024_101542 crossref_primary_10_1042_BSR20210478 crossref_primary_10_1111_1471_0528_17142 crossref_primary_10_1186_s13014_020_01564_w crossref_primary_10_3390_biom13010103 crossref_primary_10_3390_ijms222111563 crossref_primary_10_1186_s13048_020_00722_8 crossref_primary_10_3390_ijms22063019 crossref_primary_10_1080_20742835_2021_1962084 crossref_primary_10_3390_biomedicines10092060 crossref_primary_10_1093_carcin_bgac053 crossref_primary_10_31083_j_fbl2804071 crossref_primary_10_1080_03601234_2019_1633214 crossref_primary_10_1186_s12885_024_13225_2 crossref_primary_10_1016_j_ygeno_2022_110445 crossref_primary_10_7717_peerj_8347 crossref_primary_10_1016_j_ygyno_2023_01_038 crossref_primary_10_3389_fonc_2022_945518 crossref_primary_10_1016_j_ibmed_2025_100231 crossref_primary_10_3390_cancers13205230 crossref_primary_10_3390_ijms242015066 crossref_primary_10_1097_MS9_0000000000002759 crossref_primary_10_1186_s12967_019_2023_z crossref_primary_10_3390_pharmaceutics11100547 crossref_primary_10_3390_antib12040065 crossref_primary_10_1007_s12032_025_03044_1 crossref_primary_10_1080_14796694_2024_2343650 crossref_primary_10_3390_cells10040918 crossref_primary_10_1016_j_microc_2020_105046 crossref_primary_10_3389_fimmu_2022_863484 crossref_primary_10_3390_cancers13061369 crossref_primary_10_3390_diagnostics9030120 crossref_primary_10_3390_ijms21228762 crossref_primary_10_1097_jnr_0000000000000478 crossref_primary_10_1126_scitranslmed_aau7534 crossref_primary_10_1155_2020_1715064 crossref_primary_10_4155_fmc_2021_0310 crossref_primary_10_1177_03000605231164004 crossref_primary_10_1080_10717544_2018_1507062 crossref_primary_10_1080_15384101_2023_2178102 crossref_primary_10_5582_bst_2018_01052 crossref_primary_10_1016_j_prostaglandins_2018_06_001 crossref_primary_10_1080_14728222_2023_2247558 crossref_primary_10_1016_j_ijbiomac_2025_140767 crossref_primary_10_1002_cncr_33167 crossref_primary_10_3390_nu17071118 crossref_primary_10_1002_ctm2_627 crossref_primary_10_1038_s41698_019_0084_3 crossref_primary_10_1186_s13048_023_01326_8 crossref_primary_10_3390_cancers14174299 crossref_primary_10_32635_2176_9745_RBC_2022v68n1_1879 crossref_primary_10_1016_j_ijpharm_2020_119986 crossref_primary_10_3892_ol_2019_10884 crossref_primary_10_1016_j_biopha_2020_110204 crossref_primary_10_1097_COC_0000000000000900 crossref_primary_10_3390_ijms241310497 crossref_primary_10_1016_j_jep_2020_113189 crossref_primary_10_1016_j_ijbiomac_2025_139795 crossref_primary_10_1016_j_arabjc_2022_104321 crossref_primary_10_1097_MD_0000000000035246 crossref_primary_10_1080_15384101_2020_1817666 crossref_primary_10_3390_cancers13205251 crossref_primary_10_1016_j_biocel_2023_106395 crossref_primary_10_3389_fonc_2021_665945 crossref_primary_10_1016_j_omto_2023_09_001 crossref_primary_10_3390_cancers12092676 crossref_primary_10_3390_pharmaceutics14081626 crossref_primary_10_2217_fon_2021_0565 crossref_primary_10_3390_ijms241411288 crossref_primary_10_1186_s13048_020_00691_y crossref_primary_10_3389_fimmu_2023_1276694 crossref_primary_10_3389_fcell_2021_753706 crossref_primary_10_3390_biom9120788 crossref_primary_10_3390_cancers13081751 crossref_primary_10_3390_ijms22168362 crossref_primary_10_1038_s41416_021_01405_x crossref_primary_10_1002_wrna_1648 crossref_primary_10_2174_0929867326666190816232330 crossref_primary_10_1080_14796694_2024_2373680 crossref_primary_10_1007_s00432_019_03108_6 crossref_primary_10_1016_j_ijbiomac_2024_136651 crossref_primary_10_3389_fonc_2020_565666 crossref_primary_10_1038_s41467_020_19976_3 crossref_primary_10_3390_ijms23010073 crossref_primary_10_1007_s12032_023_02126_2 crossref_primary_10_1096_fj_201902259R crossref_primary_10_3390_cells10092218 crossref_primary_10_1007_s13399_021_02283_2 crossref_primary_10_3390_cancers15010299 crossref_primary_10_1016_j_biopha_2025_118141 crossref_primary_10_1016_j_mtbio_2025_102240 crossref_primary_10_1097_01_JAA_0000000000000042 crossref_primary_10_3389_fgene_2024_1333964 crossref_primary_10_3390_ijms232112839 crossref_primary_10_3389_fonc_2021_752127 crossref_primary_10_3390_cancers17071124 crossref_primary_10_3389_fonc_2020_00319 crossref_primary_10_3390_diagnostics14171898 crossref_primary_10_3390_cells12081118 crossref_primary_10_3390_cancers11091389 crossref_primary_10_1111_jcmm_18260 crossref_primary_10_1186_s13048_018_0467_z crossref_primary_10_1002_JLB_5MR0520_466R crossref_primary_10_26508_lsa_202201551 crossref_primary_10_1016_j_freeradbiomed_2021_11_019 crossref_primary_10_3390_pharmaceutics14010014 crossref_primary_10_3390_ijms22136923 crossref_primary_10_1007_s40944_021_00505_z crossref_primary_10_1002_path_6223 crossref_primary_10_3390_ijms26178393 crossref_primary_10_2147_IJN_S394383 crossref_primary_10_1186_s12967_025_06362_0 crossref_primary_10_3892_etm_2022_11351 crossref_primary_10_1007_s11523_018_0582_1 crossref_primary_10_1016_j_esmorw_2024_100038 crossref_primary_10_1186_s13048_019_0579_0 crossref_primary_10_1007_s13105_024_01059_2 crossref_primary_10_3389_fphar_2022_821344 crossref_primary_10_3390_cancers13153855 crossref_primary_10_2147_CMAR_S287152 crossref_primary_10_2147_CMAR_S268872 crossref_primary_10_1007_s12032_022_01944_0 crossref_primary_10_3390_cancers11091232 crossref_primary_10_3390_ijms19072080 crossref_primary_10_3892_mmr_2020_11452 crossref_primary_10_1016_j_intimp_2022_109052 crossref_primary_10_1016_j_ejphar_2021_173915 crossref_primary_10_1016_j_jelechem_2020_114253 crossref_primary_10_1080_15384101_2020_1731650 crossref_primary_10_1016_j_cpsurg_2019_100727 crossref_primary_10_3390_life15040638 crossref_primary_10_1016_j_tranon_2020_100863 crossref_primary_10_3390_molecules29010274 crossref_primary_10_1111_jhn_12898 crossref_primary_10_3390_cells9010149 crossref_primary_10_3390_ijms21239143 crossref_primary_10_3390_cancers17121910 crossref_primary_10_3390_ijms23063265 crossref_primary_10_3390_ijms22105059 crossref_primary_10_3390_pharmaceutics14091773 crossref_primary_10_1016_j_dyepig_2022_110386 crossref_primary_10_3390_ijms25158304 crossref_primary_10_3389_fonc_2025_1570732 crossref_primary_10_3389_fgene_2021_724785 crossref_primary_10_1093_jjco_hyz071 crossref_primary_10_1186_s13104_020_05188_x crossref_primary_10_1186_s12943_024_01967_3 crossref_primary_10_3390_ph17121606 crossref_primary_10_3390_ijms252413664 crossref_primary_10_1111_cas_14566 crossref_primary_10_3390_ijms252111760 crossref_primary_10_1016_j_addr_2021_113969 crossref_primary_10_3390_cancers13050956 crossref_primary_10_1155_2022_6575534 crossref_primary_10_1038_s41374_020_0413_8 crossref_primary_10_1007_s11626_023_00830_x crossref_primary_10_1007_s00018_023_04943_0 crossref_primary_10_1155_2019_7275289 crossref_primary_10_12688_f1000research_140640_1 crossref_primary_10_3389_fcell_2021_780510 crossref_primary_10_2147_OTT_S284261 crossref_primary_10_1097_CAD_0000000000000830 crossref_primary_10_1186_s12935_021_02295_y crossref_primary_10_3892_etm_2022_11335 crossref_primary_10_1155_2022_5864826 |
| Cites_doi | 10.18632/oncotarget.4496 10.1016/S1470-2045(11)70338-2 10.7150/jca.2.309 10.1200/JCO.2014.55.7348 10.1016/j.ygyno.2013.03.002 10.1186/s40425-016-0137-x 10.1093/annonc/mdv500 10.1016/S0140-6736(10)61268-8 10.1016/j.ygyno.2015.08.004 10.1093/annonc/mdv250 10.1016/S1470-2045(14)70244-X 10.1016/j.ygyno.2014.11.074 10.1016/S1470-2045(14)71135-0 10.1097/IGC.0b013e31821bb8aa 10.3802/jgo.2017.28.e74 10.1016/j.ccell.2014.10.006 10.1155/2012/682480 10.1038/bjc.2011.334 10.1186/s12967-016-1027-1 10.1007/s00432-016-2147-y 10.1016/j.ijgo.2013.10.001 10.1007/s40265-017-0752-y 10.18632/oncotarget.8574 10.3747/co.23.3139 10.1073/pnas.0509182102 10.5604/17322693.1184451 10.1016/S1470-2045(14)70391-2 10.1080/13543784.2016.1254616 10.1056/NEJMoa1104390 10.15557/CGO.2013.0003 10.2147/OTT.S78805 10.5301/tj.5000558 10.5604/17322693.1000548 10.1007/s10555-014-9539-8 10.1007/s40265-017-0716-2 10.1007/s13193-016-0501-9 10.2147/OTT.S119879 10.1016/S1470-2045(15)70115-4 10.1016/j.ygyno.2015.06.003 10.1158/1078-0432.CCR-12-1116 10.1016/j.ajog.2006.10.874 10.1016/j.ygyno.2011.11.021 10.1016/S1470-2045(13)70363-2 10.5732/cjc.014.10278 10.1002/cncr.24149 10.1016/j.ejca.2013.06.013 10.1200/JCO.2012.46.4057 10.1200/JCO.2013.51.4489 10.1016/j.ygyno.2017.03.505 10.1186/s12929-017-0329-9 10.1245/s10434-012-2510-4 10.1186/1757-2215-7-57 10.1056/NEJMoa1103799 10.1146/annurev.pathol.4.110807.092246 10.1038/bjc.2016.311 10.4161/hv.20738 10.1634/theoncologist.2013-0322 10.1016/S1470-2045(16)30559-9 10.1016/S1470-2045(14)70228-1 10.1016/j.ccell.2015.03.001 10.1016/j.jval.2016.01.013 10.1016/S0140-6736(15)01167-8 10.1097/IGC.0b013e31820aaafd 10.1016/j.ygyno.2006.06.014 10.1200/JCO.2010.34.3178 10.1016/j.currproblcancer.2016.11.003 10.2217/imt-2016-0034 10.1016/j.cellimm.2017.04.005 10.1056/NEJMoa1611310 10.1016/S1470-2045(15)00366-6 10.1097/IGC.0000000000000286 10.1158/1078-0432.CCR-06-2769 10.1186/s40425-015-0051-7 10.1007/s11864-014-0317-1 10.1016/j.ejca.2016.09.036 10.1093/annonc/mdw133 10.3322/caac.20095 10.1093/annonc/mdv608 10.1056/NEJMoa1505067 10.1016/S0140-6736(09)61157-0 10.1002/ijc.25423 10.1007/s40273-016-0440-x 10.1016/B978-0-12-407190-2.00007-1 10.1016/j.ejca.2012.04.001 10.2147/OTT.S98242 10.1111/j.1365-2125.2010.03635.x 10.1056/NEJMoa020177 10.1016/j.ygyno.2011.06.004 10.1016/j.ygyno.2014.02.039 10.1016/j.ejca.2016.03.005 10.1158/1078-0432.CCR-05-2670 10.18632/oncotarget.9651 10.1093/annonc/mdl357 10.1038/cgt.2016.49 10.1016/j.ccr.2014.05.016 10.3389/fonc.2014.00006 10.1016/S1470-2045(15)00086-8 10.1016/j.humpath.2011.03.003 10.1097/IGC.0000000000000051 10.1016/j.ejca.2008.10.026 10.1002/14651858.CD005340.pub4 10.1158/1538-7445.Am2015-Ct324 10.18632/oncotarget.13310 10.1200/Jco.2010.34.3178 10.1155/2016/2346585 10.2147/Ott.S78805 10.2147/Ott.S30238 10.1097/Igc.0000000000000286 10.1097/Igc.0000000000000051 10.1200/JCO.2017.35.15_suppl.5516 10.3978/j.issn.2218-676X.2015.01.04 10.2147/Ott.S119879 10.1016/s1470-2045(16)30559-9 10.1158/1078-0432.Ccr-12-1116 10.1200/Jco.2012.46.4057 10.1093/annonc/mdw374.6 10.1158/1538-7445.Am2015-Ct323 10.2147/Ott.S98242 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2017 Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2017). All Rights Reserved. |
| Copyright_xml | – notice: The Author(s) 2017 – notice: Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2017). All Rights Reserved. |
| DBID | C6C AAYXX CITATION NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 7S9 L.6 5PM |
| DOI | 10.1007/s00280-017-3501-8 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Proquest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | Oncogenes and Growth Factors Abstracts AGRICOLA MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-0843 |
| EndPage | 38 |
| ExternalDocumentID | PMC5754410 29249039 10_1007_s00280_017_3501_8 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: Narodowe Centrum Nauki grantid: UMO-2012/04/M/NZ2/00133 funderid: http://dx.doi.org/10.13039/501100004281 – fundername: ; grantid: UMO-2012/04/M/NZ2/00133 |
| GroupedDBID | --- -53 -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 6PF 78A 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFJLC AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SBL SCLPG SDE SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 Y6R YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZGI ZMTXR ZOVNA ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c503t-1f70678a7e185429e153657d05e948ade696876ebc4f4ae9619efc671291aa793 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 449 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000419437500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0344-5704 1432-0843 |
| IngestDate | Tue Nov 04 01:58:58 EST 2025 Fri Sep 05 16:15:05 EDT 2025 Thu Sep 04 15:09:34 EDT 2025 Sat Nov 08 14:35:27 EST 2025 Wed Feb 19 02:36:08 EST 2025 Sat Nov 29 04:45:31 EST 2025 Tue Nov 18 22:20:06 EST 2025 Fri Feb 21 02:33:14 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Clinical trials Biological drugs Targeted therapy Ovarian cancer |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c503t-1f70678a7e185429e153657d05e948ade696876ebc4f4ae9619efc671291aa793 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Literature Review-3 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-9786-3993 |
| OpenAccessLink | https://link.springer.com/10.1007/s00280-017-3501-8 |
| PMID | 29249039 |
| PQID | 1977617593 |
| PQPubID | 48447 |
| PageCount | 22 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5754410 proquest_miscellaneous_3206222182 proquest_miscellaneous_1978320768 proquest_journals_1977617593 pubmed_primary_29249039 crossref_primary_10_1007_s00280_017_3501_8 crossref_citationtrail_10_1007_s00280_017_3501_8 springer_journals_10_1007_s00280_017_3501_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-01-01 |
| PublicationDateYYYYMMDD | 2018-01-01 |
| PublicationDate_xml | – month: 01 year: 2018 text: 2018-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | Cancer chemotherapy and pharmacology |
| PublicationTitleAbbrev | Cancer Chemother Pharmacol |
| PublicationTitleAlternate | Cancer Chemother Pharmacol |
| PublicationYear | 2018 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | Ferron, De Rauglaudre, Ray-Coquard, Lesoin, Joly, Lortholary, Raban, Peron, Malaurie-Agostini, Gouy, Kaminsky, Meunier, Alexandre, Berton-Rigaud, Coussy, Favier, Venat-Bouvet, Marmion, Combe, Pujade-Lauraine (CR67) 2016 Lluesma, Wolfer, Harari, Kandalaft (CR106) 2016; 4 Yap, Sandhu, Carden, de Bono (CR72) 2011; 61 Krishnan, Berek, Dorigo (CR111) 2017; 41 Marchetti, De Felice, Palaia, Musella, Di Donato, Gasparri, Musio, Muzii, Tombolini, Panici (CR48) 2015; 7 Hinde, Epstein, Cook, Embleton, Perren, Sculpher (CR57) 2016; 19 CR38 CR37 Murata, Zhang, Finch, Zhang, Campo, Breuer (CR74) 2016 Sato, Olson, Ahn, Bundy, Nishikawa, Qian, Jungbluth, Frosina, Gnjatic, Ambrosone, Kepner, Odunsi, Ritter, Lele, Chen, Ohtani, Old, Odunsi (CR108) 2005; 102 van Meurs, Tajik, Hof, Vergote, Kenter, Mol, Buist, Bossuyt (CR20) 2013; 49 Tewari, Java, Eskander, Monk, Burger (CR41) 2016; 27 CR31 CR30 Berek, Edwards, Parker, DeMars, Herzog, Lentz, Morris, Akerley, Holloway, Method, Plaxe, Walker, Friccius-Quecke, Krasner (CR126) 2014; 24 (CR10) 2015 Katsumata, Yasuda, Takahashi, Isonishi, Jobo, Aoki, Tsuda, Sugiyama, Kodama, Kimura, Ochiai, Noda, Grp (CR16) 2009; 374 Gotlieb, Amant, Advani, Goswami, Hirte, Provencher, Somani, Yamada, Tamby, Vergote (CR133) 2012; 13 Aravantinos, Pectasides (CR39) 2014; 7 Kujawa, Lisowska (CR2) 2015; 69 Pfisterer, du Bois, Sehouli, Loibl, Reinartz, Reuss, Canzler, Belau, Jackisch, Kimmig, Wollschlaeger, Heilmann, Hilpert (CR115) 2006; 17 Mantia-Smaldone, Corr, Chu (CR121) 2012; 8 Lopez-Guerrero, Romero, Poveda (CR24) 2015; 34 Gaillard, Secord, Monk (CR110) 2016; 3 Ledermann, Harter, Gourley, Friedlander, Vergote, Rustin, Scott, Meier, Shapira-Frommer, Safra, Matei, Fielding, Spencer, Dougherty, Orr, Hodgson, Barrett, Matulonis (CR79) 2014; 15 Alipour, Zoghi, Khalili, Hirbod-Mobarakeh, Emens, Rezaei (CR112) 2016; 8 Borlak, Langer, Spanel, Schondorfer, Dittrich (CR132) 2016; 7 Colombo, Mangili, Mammoliti, Kalling, Tholander, Sternas, Buzenet, Chamberlain (CR134) 2012; 125 Awasthi, Schwarz (CR63) 2015; 8 Rutkowski, Śpiewankiewicz, Herman, Jastrzębski, Kładny, Kojs, Krzakowski, Polkowski, Wyrwicz, Wysocki, Zdzienicki, Zegarski (CR32) 2014; 64 Mirza, Monk, Herrstedt, Oza, Mahner, Redondo, Fabbro, Ledermann, Lorusso, Vergote, Ben-Baruch, Marth, Madry, Christensen, Berek, Dorum, Tinker, du Bois, Gonzalez-Martin, Follana, Benigno, Rosenberg, Gilbert, Rimel, Buscema, Balser, Agarwal, Matulonis, Investigators (CR87) 2016; 375 Seeber, Braicu, Untergasser, Nassir, Fong, Botta, Gastl, Fiegl, Zeimet, Sehouli, Spizzo (CR128) 2015; 6 Chester, Dorigo, Berek, Kohrt (CR109) 2015; 3 Elit, Hirte (CR66) 2013 Walker, Brady, DiSilvestro (CR22) 2016; 141 Laas, Luyckx, De Cuypere, Selle, Darai, Querleu, Rouzier, Chereau (CR27) 2014; 24 Vergote, Marth, Coleman (CR105) 2015; 34 Morano, Aggarwal, Love, Richard, Esquivel, Bowne (CR123) 2016; 23 Prat, Oncology (CR8) 2014; 124 Aghajanian, Goff, Nycum, Wang, Husain, Blank (CR47) 2015; 139 du Bois, Reuss, Pujade-Lauraine, Harter, Ray-Coquard, Pfisterer (CR9) 2009; 115 Tagawa, Morgan, Yen, Mortimer (CR135) 2012; 2012 Cho, Shih (CR7) 2009; 4 CR51 Armstrong, White, Weil, Phillips, Coleman (CR102) 2013; 129 Karlan, Oza, Richardson, Provencher, Hansen, Buck, Chambers, Ghatage, Pippitt, Brown, Covens, Nagarkar, Davy, Leath, Nguyen, Stepan, Weinreich, Tassoudji, Sun, Vergote (CR70) 2012; 30 du Bois, Floquet, Kim, Rau, del Campo, Friedlander, Pignata, Fujiwara, Vergote, Colombo, Mirza, Monk, Kimmig, Ray-Coquard, Zang, Diaz-Padilla, Baumann, Mouret-Reynier, Kim, Kurzeder, Lesoin, Vasey, Marth, Canzler, Scambia, Shimada, Calvert, Pujade-Lauraine, Kim, Herzog, Mitrica, Schade-Brittinger, Wang, Crescenzo, Harter (CR61) 2014; 32 Sabbatini, Harter, Scambia, Sehouli, Meier, Wimberger, Baumann, Kurzeder, Schmalfeldt, Cibula, Bidzinski, Casado, Martoni, Colombo, Holloway, Selvaggi, Li, del Campo, Cwiertka, Pinter, Vermorken, Pujade-Lauraine, Scartoni, Bertolotti, Simonelli, Capriati, Maggi, Berek, Pfisterer (CR120) 2013; 31 Drerup, Liu, Padron, Murthy, Hurez, Zhang, Curiel (CR98) 2015; 16 Du Bois, Kristensen, Ray-Coquard, Reuss, Pignata, Colombo, Denison, Vergote, Del Campo, Ottevanger, Heubner, Minarik, Sevin, de Gregorio, Bidziński, Pfisterer, Malander, Hilpert, Mirza, Scambia, Meier, Nicoletto, Bjorge, Lortholary, Sailer, Merger, Harter, Consortium (CR65) 2016; 17 Wolford, Bai, Eskander, Keller, Minion, Chan, Monk, Tewari (CR96) 2017 Floquet, Vergote, Colombo, Fiane, Monk, Reinthaller, Calvert, Herzog, Meier, Kim, del Campo, Friedlander, Pisano, Isonishi, Crescenzo, Barrett, Wang, Mitrica, du Bois (CR62) 2015; 136 Oza, Cibula, Benzaquen, Poole, Mathijssen, Sonke, Colombo, Spacek, Vuylsteke, Hirte, Mahner, Plante, Schmalfeldt, Mackay, Rowbottom, Lowe, Dougherty, Barrett, Friedlander (CR82) 2015; 16 (CR15) 2009 CR69 CR68 CR64 Katsumata, Yasuda, Isonishi, Takahashi, Michimae, Kimura, Aoki, Jobo, Kodama, Terauchi, Sugiyama, Ochiai, Grp (CR17) 2013; 14 Papa, Caruso, Strudel, Tomao, Tomao (CR92) 2016; 14 Sabbatini, Dupont, Aghajanian, Derosa, Poynor, Anderson, Hensley, Livingston, Iasonos, Spriggs, McGuire, Reinartz, Schneider, Grande, Lele, Rodabaugh, Kepner, Ferrone, Odunsi (CR116) 2006; 12 Jain (CR36) 2014; 26 Pignata, Lorusso, Scambia, Sambataro, Tamberi, Cinieri, Mosconi, Orditura, Brandes, Arcangeli, Panici, Pisano, Cecere, Di Napoli, Raspagliesi, Maltese, Salutari, Ricci, Daniele, Piccirillo, Di Maio, Gallo, Perrone, investigators (CR60) 2015; 16 Smolle, Taucher, Haybaeck (CR122) 2014; 34 Baumann, Pfisterer, Wimberger, Burchardi, Kurzeder, du Bois, Loibl, Sehouli, Huober, Schmalfeldt, Vergote, Luck, Wagner (CR130) 2011; 123 Pujade-Lauraine, Ledermann, Penson, Oza, Korach, Huzarski, Poveda, Pignata, Friedlander, Colombo (CR80) 2017; 145 Harter, Sehouli, Reuss, Hasenburg, Scambia, Cibula, Mahner, Vergote, Reinthaller, Burges, Hanker, Polcher, Kurzeder, Canzler, Petry, Obermair, Petru, Schmalfeldt, Lorusso, du Bois (CR28) 2011; 21 Ledermann, Canevari, Thigpen (CR103) 2015; 26 Bhatt, Glehen (CR33) 2016; 7 Lisowska, Olbryt, Student, Kujawa, Cortez, Simek, Dansonka-Mieszkowska, Rzepecka, Tudrej, Kupryjanczyk (CR4) 2016; 142 Chan, Herzog, Hu, Monk, Kiet, Blansit, Kapp, Yu (CR55) 2014; 19 Gray, Benigno, Berek, Chang, Mason, Mileshkin, Mitchell, Moradi, Recio, Michener, Secord, Tchabo, Chan, Young, Kohrt, Gargosky, Goh (CR118) 2016; 4 Yi, Zeng, Kuang, Cao, Zheng, Zhang, Liao, Yang (CR49) 2017; 10 Oza, Cook, Pfisterer, Embleton, Ledermann, Pujade-Lauraine, Kristensen, Carey, Beale, Cervantes, Park-Simon, Rustin, Joly, Mirza, Plante, Quinn, Poveda, Jayson, Stark, Swart, Farrelly, Kaplan, Parmar, Perren, Investigators (CR44) 2015; 16 Aghajanian (CR45) 2006; 102 Monk, Herzog, Kaye, Krasner, Vermorken, Muggia, Pujade-Lauraine, Park, Parekh, Poveda (CR25) 2012; 48 CR76 Perren, Swart, Pfisterer, Ledermann, Pujade-Lauraine, Kristensen, Carey, Beale, Cervantes, Kurzeder, du Bois, Sehouli, Kimmig, Stahle, Collinson, Essapen, Gourley, Lortholary, Selle, Mirza, Leminen, Plante, Stark, Qian, Parmar, Oza, Investigators (CR43) 2011; 365 Pujade-Lauraine, Hilpert, Weber, Reuss, Poveda, Kristensen, Sorio, Vergote, Witteveen, Bamias, Pereira, Wimberger, Oaknin, Mirza, Follana, Bollag, Ray-Coquard (CR46) 2014; 32 CR75 Rustin, van der Burg, Griffin, Guthrie, Lamont, Jayson, Kristensen, Mediola, Coens, Qian, Parmar, Swart, Mrc (CR13) 2010; 376 Liu, Konstantinopoulos, Matulonis (CR77) 2014; 133 Ries, Cannarile, Hoves, Benz, Wartha, Runza, Rey-Giraud, Pradel, Feuerhake, Klaman, Jones, Jucknischke, Scheiblich, Kaluza, Gorr, Walz, Abiraj, Cassier, Sica, Gomez-Roca, de Visser, Italiano, Le Tourneau, Delord, Levitsky, Blay, Ruttinger (CR53) 2014; 25 Ledermann, Embleton, Raja, Perren, Jayson, Rustin, Kaye, Hirte, Eisenhauer, Vaughan, Friedlander, Gonzalez-Martin, Stark, Clark, Farrelly, Swart, Cook, Kaplan, Parmar, Collaborators (CR59) 2016; 387 Zhang, Conejo-Garcia, Katsaros, Gimotty, Massobrio, Regnani, Makrigiannakis, Gray, Schlienger, Liebman, Rubin, Coukos (CR107) 2003; 348 Konecny, Kristeleit (CR54) 2016; 115 Lutz (CR99) 2015; 4 Urbański (CR23) 2007; 3 Topalian, Drake, Pardoll (CR114) 2015; 27 Michalarea, Lorente, Lopez, Carreira, Hassam, Parmar, Sathiyayogan, Turner, Hall, Fandos, Seeramreddi, Decordova, Swales, Ruddle, Raynaud, Tunariu, Attard, Molife, Banerji, Plummer, de Bono, Yap (CR85) 2015 Tappenden, Harnan, Ren, Thokala, Wong, Mukuria, Green, Pledge, Tidy (CR95) 2017; 35 Friedlander, Trimble, Tinker, Alberts, Avall-Lundqvist, Brady, Harter, Pignata, Pujade-Lauraine, Sehouli, Vergote, Beale, Bekkers, Calvert, Copeland, Glasspool, Gonzalez-Martin, Katsaros, Kim, Miller, Provencher, Rubinstein, Atri, Zeimet, Bacon, Kitchener, Stuart, InterGrp (CR14) 2011; 21 CR89 Sato, Itamochi (CR101) 2016; 9 Bignotti, Tassi, Calza, Ravaggi, Bandiera, Rossi, Donzelli, Pasinetti, Pecorelli, Santin (CR3) 2007; 196 Kurman, Shih (CR1) 2011; 42 Burges, Wimberger, Kumper, Gorbounova, Sommer, Schmalfeldt, Pfisterer, Lichinitser, Makhson, Moiseyenko, Lahr, Schulze, Jager, Strohlein, Heiss, Gottwald, Lindhofer, Kimmig (CR131) 2007; 13 Lorusso, Scambia, Pignata, Sorio, Amadio, Lepori, Mosconi, Pisano, Mangili, Maltese, Sabbatini, Artioli, Gamucci, Di Napoli, Capoluongo, Ludovini, Raspagliesi, Ferrandina (CR26) 2016; 27 Chan, Brady, Penson, Huang, Birrer, Walker, DiSilvestro, Rubin, Martin, Davidson, Huh, O’Malley, Boente, Michael, Monk (CR18) 2016; 374 Karbach, Neumann, Brand, Wahle, Siegel, Maeurer, Ritter, Tsuji, Gnjatic, Old, Ritter, Jager (CR119) 2012; 18 Wolford, Tewari (CR29) 2017; 28 Śpiewankiewicz, Osuch, Kuśnierz, Symonides, Smorczewska (CR34) 2013; 11 Iwai, Hamanishi, Chamoto, Honjo (CR113) 2017; 24 CR19 Ruf, Kluge, Jager, Burges, Volovat, Heiss, Hess, Wimberger, Brandt, Lindhofer (CR124) 2010; 69 Matulonis, Penson, Domchek, Kaufman, Shapira-Frommer, Audeh, Kaye, Molife, Gelmon, Robertson, Mann, Ho, Coleman (CR81) 2016; 27 Goswami, Ghosh, Ghosh, Sarkar, Bose, Baral (CR52) 2017; 316 Duong, Wright, Yin, Martin-Nunez, Ghatage, Fung-Kee-Fung (CR56) 2016; 23 (CR91) 2017 Kluzek, Białkowska, Koczorowska, Zdzienicka (CR73) 2012; 66 Matulonis, Wulf, Barry, BY Karlan (3501_CR70) 2012; 30 EA Eisenhauer (3501_CR11) 2009; 45 JE Wolford (3501_CR29) 2017; 28 3501_CR76 3501_CR75 YY Syed (3501_CR88) 2017; 77 KS Tewari (3501_CR41) 2016; 27 MM Heiss (3501_CR127) 2010; 127 S Pignata (3501_CR60) 2015; 16 GJ Rustin (3501_CR13) 2010; 376 E Pujade-Lauraine (3501_CR80) 2017; 145 P Rutkowski (3501_CR32) 2014; 64 R Rouzier (3501_CR50) 2017; 70 CH Ries (3501_CR53) 2014; 25 JF Liu (3501_CR77) 2014; 133 A Bois du (3501_CR9) 2009; 115 G Aravantinos (3501_CR39) 2014; 7 P Harter (3501_CR28) 2011; 21 J Walker (3501_CR22) 2016; 141 V Krishnan (3501_CR111) 2017; 41 D Lorusso (3501_CR26) 2016; 27 A Bergamini (3501_CR100) 2016; 25 D Seimetz (3501_CR125) 2011; 2 SL Topalian (3501_CR114) 2015; 27 JE Wolford (3501_CR96) 2017 3501_CR64 A Bois du (3501_CR61) 2014; 32 3501_CR69 JA Ledermann (3501_CR93) 2016; 60 3501_CR68 C Guo (3501_CR117) 2013; 119 KM Lisowska (3501_CR4) 2016; 142 J Prat (3501_CR8) 2014; 124 JM Drerup (3501_CR98) 2015; 16 J Pfisterer (3501_CR115) 2006; 17 E Laas (3501_CR27) 2014; 24 S Sato (3501_CR101) 2016; 9 V Michalarea (3501_CR85) 2015 KA Kujawa (3501_CR2) 2015; 69 KM Lisowska (3501_CR5) 2014; 4 J Karbach (3501_CR119) 2012; 18 3501_CR51 S Alipour (3501_CR112) 2016; 8 E Smolle (3501_CR122) 2014; 34 C Aghajanian (3501_CR45) 2006; 102 Y Iwai (3501_CR113) 2017; 24 E (3501_CR10) 2015 K Kluzek (3501_CR73) 2012; 66 TJ Perren (3501_CR43) 2011; 365 A Bhatt (3501_CR33) 2016; 7 M Friedlander (3501_CR14) 2011; 21 A Cheung (3501_CR97) 2016; 7 JA Ledermann (3501_CR103) 2015; 26 N Awasthi (3501_CR63) 2015; 8 M Duong (3501_CR56) 2016; 23 BJ Monk (3501_CR25) 2012; 48 A Papa (3501_CR92) 2016; 14 M Fossati (3501_CR129) 2015; 138 A Floquet (3501_CR62) 2015; 136 KR Cho (3501_CR7) 2009; 4 RK Jain (3501_CR36) 2014; 26 EM Swisher (3501_CR90) 2017; 18 RA Burger (3501_CR42) 2011; 365 C Chester (3501_CR109) 2015; 3 JK Chan (3501_CR55) 2014; 19 N Bakrin (3501_CR35) 2012; 19 A Burges (3501_CR131) 2007; 13 FA Raja (3501_CR58) 2011; 105 E Sato (3501_CR108) 2005; 102 GM Mantia-Smaldone (3501_CR121) 2012; 8 JF Liu (3501_CR83) 2014; 15 P Ruf (3501_CR124) 2010; 69 J McLachlan (3501_CR78) 2016; 102 3501_CR31 3501_CR30 3501_CR37 G Ferron (3501_CR67) 2016 UA Matulonis (3501_CR81) 2016; 27 P Sabbatini (3501_CR120) 2013; 31 JA Ledermann (3501_CR59) 2016; 387 N Katsumata (3501_CR16) 2009; 374 3501_CR38 A Basta (3501_CR6) 2015; 11 JS Berek (3501_CR126) 2014; 24 LJ Scott (3501_CR86) 2017; 77 A Du Bois (3501_CR65) 2016; 17 C Marchetti (3501_CR48) 2015; 7 MR Mirza (3501_CR87) 2016; 375 WF Morano (3501_CR123) 2016; 23 J Ledermann (3501_CR79) 2014; 15 WH Gotlieb (3501_CR133) 2012; 13 L Zhang (3501_CR107) 2003; 348 UA Matulonis (3501_CR84) 2015 JK Chan (3501_CR18) 2016; 374 3501_CR21 GE Konecny (3501_CR54) 2016; 115 B Śpiewankiewicz (3501_CR34) 2013; 11 L Rossi (3501_CR40) 2017; 8 KK Goswami (3501_CR52) 2017; 316 DK Armstrong (3501_CR102) 2013; 129 E Bignotti (3501_CR3) 2007; 196 TA Yap (3501_CR72) 2011; 61 L Elit (3501_CR66) 2013 SM Lluesma (3501_CR106) 2016; 4 3501_CR104 K Urbański (3501_CR23) 2007; 3 3501_CR94 S Yi (3501_CR49) 2017; 10 ESMO2017. Rucaparib (3501_CR91) 2017 AM Oza (3501_CR44) 2015; 16 RJ Kurman (3501_CR1) 2011; 42 3501_CR19 P Tappenden (3501_CR95) 2017; 35 P Sabbatini (3501_CR116) 2006; 12 N Katsumata (3501_CR17) 2013; 14 IB Vergote (3501_CR105) 2015; 34 K Baumann (3501_CR130) 2011; 123 E Pujade-Lauraine (3501_CR46) 2014; 32 C Aghajanian (3501_CR47) 2015; 139 BJ Monk (3501_CR71) 2014; 15 T Tagawa (3501_CR135) 2012; 2012 HJ Gray (3501_CR118) 2016; 4 J Borlak (3501_CR132) 2016; 7 N Colombo (3501_CR134) 2012; 125 RJ Lutz (3501_CR99) 2015; 4 JA Lopez-Guerrero (3501_CR24) 2015; 34 S Murata (3501_CR74) 2016 OW Foley (3501_CR12) 2013; 27 HS Meurs van (3501_CR20) 2013; 49 3501_CR89 S Hinde (3501_CR57) 2016; 19 EMA (3501_CR15) 2009 AM Oza (3501_CR82) 2015; 16 A Seeber (3501_CR128) 2015; 6 SL Gaillard (3501_CR110) 2016; 3 |
| References_xml | – volume: 6 start-page: 25017 issue: 28 year: 2015 end-page: 25023 ident: CR128 article-title: Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab publication-title: Oncotarget doi: 10.18632/oncotarget.4496 – volume: 13 start-page: 154 issue: 2 year: 2012 end-page: 162 ident: CR133 article-title: Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70338-2 – volume: 2 start-page: 309 year: 2011 end-page: 316 ident: CR125 article-title: Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab [removab (R)] publication-title: J Cancer doi: 10.7150/jca.2.309 – volume: 32 start-page: 3374 issue: 30 year: 2014 end-page: 3382 ident: CR61 article-title: Incorporation of pazopanib in maintenance therapy of ovarian cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2014.55.7348 – volume: 129 start-page: 452 issue: 3 year: 2013 end-page: 458 ident: CR102 article-title: Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2013.03.002 – ident: CR68 – volume: 4 start-page: 34 year: 2016 ident: CR118 article-title: Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial publication-title: J Immunother Cancer doi: 10.1186/s40425-016-0137-x – volume: 27 start-page: 114 issue: 1 year: 2016 end-page: 121 ident: CR41 article-title: Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG oncology/gynecologic oncology group study publication-title: Ann Oncol doi: 10.1093/annonc/mdv500 – volume: 376 start-page: 1155 issue: 9747 year: 2010 end-page: 1163 ident: CR13 article-title: Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(10)61268-8 – ident: CR51 – volume: 139 start-page: 10 issue: 1 year: 2015 end-page: 16 ident: CR47 article-title: Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2015.08.004 – volume: 26 start-page: 2034 issue: 10 year: 2015 end-page: 2043 ident: CR103 article-title: Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments publication-title: Ann Oncol doi: 10.1093/annonc/mdv250 – volume: 15 start-page: 799 issue: 8 year: 2014 end-page: 808 ident: CR71 article-title: Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70244-X – volume: 136 start-page: 37 issue: 1 year: 2015 end-page: 42 ident: CR62 article-title: Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2014.11.074 – volume: 16 start-page: 87 issue: 1 year: 2015 end-page: 97 ident: CR82 article-title: Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71135-0 – volume: 21 start-page: 771 issue: 4 year: 2011 end-page: 775 ident: CR14 article-title: Clinical trials in recurrent ovarian cancer publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0b013e31821bb8aa – volume: 28 start-page: 1 issue: 5 year: 2017 end-page: 12 ident: CR29 article-title: Highlights from the gynecologic oncology track at the 2017 annual meeting of the American society of clinical oncology publication-title: J Gynecol Oncol doi: 10.3802/jgo.2017.28.e74 – volume: 26 start-page: 605 issue: 5 year: 2014 end-page: 622 ident: CR36 article-title: Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia publication-title: Cancer Cell doi: 10.1016/j.ccell.2014.10.006 – volume: 2012 start-page: 682480 year: 2012 ident: CR135 article-title: Ovarian cancer: opportunity for targeted therapy publication-title: J Oncol doi: 10.1155/2012/682480 – year: 2009 ident: CR15 publication-title: EMA approval: avastin autorization details – ident: CR19 – volume: 105 start-page: 884 issue: 7 year: 2011 end-page: 889 ident: CR58 article-title: Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer publication-title: Brit J Cancer doi: 10.1038/bjc.2011.334 – volume: 14 start-page: 267 year: 2016 ident: CR92 article-title: Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment publication-title: J Transl Med doi: 10.1186/s12967-016-1027-1 – volume: 142 start-page: 1239 issue: 6 year: 2016 end-page: 1252 ident: CR4 article-title: Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival publication-title: J Cancer Res Clin doi: 10.1007/s00432-016-2147-y – volume: 124 start-page: 1 issue: 1 year: 2014 end-page: 5 ident: CR8 article-title: Staging classification for cancer of the ovary, fallopian tube, and peritoneum publication-title: Int J Gynaecol Obstet doi: 10.1016/j.ijgo.2013.10.001 – volume: 77 start-page: 1029 issue: 9 year: 2017 end-page: 1034 ident: CR86 article-title: Niraparib: first global approval publication-title: Drugs doi: 10.1007/s40265-017-0752-y – volume: 4 start-page: 28 issue: 2 year: 2016 ident: CR106 article-title: Cancer vaccines in ovarian cancer. How can we improve? publication-title: Biomedicines – volume: 7 start-page: 28059 issue: 19 year: 2016 end-page: 28074 ident: CR132 article-title: Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fc gamma receptors publication-title: Oncotarget doi: 10.18632/oncotarget.8574 – volume: 23 start-page: E461 issue: 5 year: 2016 end-page: E467 ident: CR56 article-title: The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada publication-title: Curr Oncol doi: 10.3747/co.23.3139 – volume: 102 start-page: 18538 issue: 51 year: 2005 end-page: 18543 ident: CR108 article-title: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0509182102 – volume: 69 start-page: 1275 year: 2015 end-page: 1290 ident: CR2 article-title: Ovarian cancer—from biology to clinic publication-title: Postep Hig Med Dosw doi: 10.5604/17322693.1184451 – year: 2013 ident: CR66 article-title: Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options publication-title: Oncotargets Ther – volume: 15 start-page: 1207 issue: 11 year: 2014 end-page: 1214 ident: CR83 article-title: Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70391-2 – volume: 25 start-page: 1405 issue: 12 year: 2016 end-page: 1412 ident: CR100 article-title: Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer publication-title: Expert Opin Investig Drugs doi: 10.1080/13543784.2016.1254616 – volume: 365 start-page: 2473 issue: 26 year: 2011 end-page: 2483 ident: CR42 article-title: Incorporation of bevacizumab in the primary treatment of ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1104390 – volume: 11 start-page: 9 issue: 1 year: 2013 ident: CR34 article-title: Hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of patients with disseminated intraperitoneal malignancy: preliminary report publication-title: Curr Gynecol Oncol doi: 10.15557/CGO.2013.0003 – volume: 8 start-page: 3691 year: 2015 end-page: 3701 ident: CR63 article-title: Profile of nintedanib in the treatment of solid tumors: the evidence to date publication-title: Oncotargets Ther doi: 10.2147/OTT.S78805 – volume: 102 start-page: 433 issue: 5 year: 2016 end-page: 440 ident: CR78 article-title: The current status of PARP inhibitors in ovarian cancer publication-title: Tumori doi: 10.5301/tj.5000558 – volume: 66 start-page: 13 year: 2012 ident: CR73 article-title: Inhibitory polimerazy poli(ADP-rybozy) (PARP) w terapii nowotworów z mutacjami BRCA1/2. Advances in hygiene and experimental medicine publication-title: Postepy Hig Med Dosw doi: 10.5604/17322693.1000548 – volume: 34 start-page: 41 issue: 1 year: 2015 end-page: 52 ident: CR105 article-title: Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications publication-title: Cancer Metastasis Rev doi: 10.1007/s10555-014-9539-8 – volume: 11 start-page: 11 issue: 5 year: 2015 ident: CR6 article-title: Recommendation of the Polish society of oncological gynaecology on the diagnosis and treatment of epithelial ovarian cancer publication-title: Oncol Clin Pract – volume: 77 start-page: 585 issue: 5 year: 2017 end-page: 592 ident: CR88 article-title: Rucaparib: first global approval publication-title: Drugs doi: 10.1007/s40265-017-0716-2 – ident: CR89 – volume: 3 start-page: 14 issue: 11 year: 2016 ident: CR110 article-title: The role of immune checkpoint inhibition in the treatment of ovarian cancer publication-title: Gynecol Oncol Res Pract – volume: 7 start-page: 188 issue: 2 year: 2016 end-page: 197 ident: CR33 article-title: The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer: a review publication-title: India J Surg Oncol doi: 10.1007/s13193-016-0501-9 – ident: CR30 – volume: 10 start-page: 973 year: 2017 end-page: 984 ident: CR49 article-title: Anti-angiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis publication-title: Oncotargets Ther doi: 10.2147/OTT.S119879 – volume: 16 start-page: 561 issue: 5 year: 2015 end-page: 568 ident: CR60 article-title: Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)70115-4 – volume: 138 start-page: 343 issue: 2 year: 2015 end-page: 351 ident: CR129 article-title: Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2015.06.003 – volume: 18 start-page: 5449 issue: 19 year: 2012 end-page: 5459 ident: CR119 article-title: Phase I clinical trial of mixed bacterial vaccine (coley’s toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-1116 – volume: 196 start-page: 245 issue: 3 year: 2007 end-page: 246 ident: CR3 article-title: Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2006.10.874 – volume: 125 start-page: 42 issue: 1 year: 2012 end-page: 47 ident: CR134 article-title: A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2011.11.021 – volume: 14 start-page: 1020 issue: 10 year: 2013 end-page: 1026 ident: CR17 article-title: Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70363-2 – year: 2015 ident: CR85 article-title: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients publication-title: Cancer Res – volume: 34 start-page: 41 issue: 1 year: 2015 end-page: 49 ident: CR24 article-title: Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer publication-title: Chin J Cancer doi: 10.5732/cjc.014.10278 – volume: 115 start-page: 1234 issue: 6 year: 2009 end-page: 1244 ident: CR9 article-title: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO) publication-title: Cancer doi: 10.1002/cncr.24149 – volume: 49 start-page: 3191 issue: 15 year: 2013 end-page: 3201 ident: CR20 article-title: Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European organisation for research and treatment of cancer 55971 randomised trial publication-title: Eur J Cancer doi: 10.1016/j.ejca.2013.06.013 – volume: 31 start-page: 1554 issue: 12 year: 2013 end-page: 1561 ident: CR120 article-title: Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study publication-title: J Clin Oncol doi: 10.1200/JCO.2012.46.4057 – ident: CR69 – ident: CR94 – volume: 64 start-page: 7 issue: 6 year: 2014 ident: CR32 article-title: Polish clinical practice guidelines on hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductice surgery (CRS) in peritoneal malignancy treatment publication-title: Nowotw J Oncol – year: 2015 ident: CR10 publication-title: Advanced (stage III-IV) ovarian cancer surgery. Quality indicators. Complete report – volume: 32 start-page: 1302 issue: 13 year: 2014 end-page: 1308 ident: CR46 article-title: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.2013.51.4489 – ident: CR38 – volume: 145 start-page: 220 year: 2017 ident: CR80 article-title: Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum sensitive relapsed ovarian cancer: results from the phase III SOLO2 study publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2017.03.505 – volume: 24 start-page: 26 year: 2017 ident: CR113 article-title: Cancer immunotherapies targeting the PD-1 signaling pathway publication-title: J Biomed Sci doi: 10.1186/s12929-017-0329-9 – volume: 19 start-page: 7 year: 2012 ident: CR35 article-title: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients publication-title: Ann Surg Oncol doi: 10.1245/s10434-012-2510-4 – volume: 7 start-page: 57 year: 2014 ident: CR39 article-title: Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review publication-title: J Ovarian Res doi: 10.1186/1757-2215-7-57 – volume: 365 start-page: 2484 issue: 26 year: 2011 end-page: 2496 ident: CR43 article-title: A phase 3 trial of bevacizumab in ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1103799 – volume: 4 start-page: 287 year: 2009 end-page: 313 ident: CR7 article-title: Ovarian cancer publication-title: Annu Rev Pathol Mech Dis doi: 10.1146/annurev.pathol.4.110807.092246 – volume: 115 start-page: 1157 issue: 10 year: 2016 end-page: 1173 ident: CR54 article-title: PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions publication-title: Br J Cancer doi: 10.1038/bjc.2016.311 – volume: 8 start-page: 1179 issue: 9 year: 2012 end-page: 1191 ident: CR121 article-title: Immunotherapy in ovarian cancer publication-title: Hum Vaccin Immunother doi: 10.4161/hv.20738 – volume: 19 start-page: 523 issue: 5 year: 2014 end-page: 527 ident: CR55 article-title: Bevacizumab in treatment of high-risk ovarian cancer-a cost-effectiveness analysis publication-title: Oncologist doi: 10.1634/theoncologist.2013-0322 – volume: 18 start-page: 75 issue: 1 year: 2017 end-page: 87 ident: CR90 article-title: Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30559-9 – volume: 15 start-page: 852 issue: 8 year: 2014 end-page: 861 ident: CR79 article-title: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70228-1 – volume: 27 start-page: 450 issue: 4 year: 2015 end-page: 461 ident: CR114 article-title: Immune checkpoint blockade: a common denominator approach to cancer therapy publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.03.001 – volume: 19 start-page: 431 issue: 4 year: 2016 end-page: 439 ident: CR57 article-title: The cost-effectiveness of bevacizumab in advanced ovarian cancer using evidence from the ICON7 trial publication-title: Value Health doi: 10.1016/j.jval.2016.01.013 – volume: 387 start-page: 1066 issue: 10023 year: 2016 end-page: 1074 ident: CR59 article-title: Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(15)01167-8 – volume: 3 start-page: 8 issue: 6 year: 2007 ident: CR23 article-title: Consolidation therapy of ovarian cancer publication-title: Onkologia w Praktyce Klinicznej – volume: 7 start-page: 7 issue: 11 year: 2015 ident: CR48 article-title: Efficacy and toxicity of bevazicumab in recurrent ovarian disease: an update meta-analysis on phase III trials publication-title: Oncotarget – volume: 21 start-page: 289 issue: 2 year: 2011 end-page: 295 ident: CR28 article-title: Prospective validation study of a predictive score for operability of recurrent ovarian cancer the multicenter intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0b013e31820aaafd – volume: 102 start-page: 131 issue: 2 year: 2006 end-page: 133 ident: CR45 article-title: The role of bevacizumab in ovarian cancer—an evolving story publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2006.06.014 – year: 2017 ident: CR96 article-title: Evaluating the cost-effectiveness of current FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer publication-title: J Clin Oncol – year: 2015 ident: CR84 article-title: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: final results of the BKM120 plus olaparib cohort publication-title: Cancer Res – volume: 30 start-page: 362 issue: 4 year: 2012 end-page: 371 ident: CR70 article-title: Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2010.34.3178 – volume: 4 start-page: 118 issue: 1 year: 2015 end-page: 126 ident: CR99 article-title: Targeting the folate receptor for the treatment of ovarian cancer publication-title: Transl Cancer Res – volume: 141 start-page: 208 year: 2016 ident: CR22 article-title: A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: an NRG Oncology Study publication-title: Gynecol Oncol – volume: 41 start-page: 48 issue: 1 year: 2017 end-page: 63 ident: CR111 article-title: Immunotherapy in ovarian cancer publication-title: Curr Probl Cancer doi: 10.1016/j.currproblcancer.2016.11.003 – ident: CR21 – volume: 8 start-page: 1193 issue: 10 year: 2016 end-page: 1204 ident: CR112 article-title: Specific immunotherapy in ovarian cancer: a systematic review publication-title: Immunotherapy doi: 10.2217/imt-2016-0034 – volume: 34 start-page: 1553 issue: 4 year: 2014 end-page: 1561 ident: CR122 article-title: Malignant ascites in ovarian cancer and the role of targeted therapeutics publication-title: Anticancer Res – ident: CR75 – volume: 316 start-page: 10 year: 2017 ident: CR52 article-title: Tumor promoting role of anti-tumor macrophages in tumor microenvironment publication-title: Cell Immunol doi: 10.1016/j.cellimm.2017.04.005 – volume: 375 start-page: 2154 issue: 22 year: 2016 end-page: 2164 ident: CR87 article-title: Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1611310 – volume: 17 start-page: 78 issue: 1 year: 2016 end-page: 89 ident: CR65 article-title: Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00366-6 – volume: 24 start-page: 1583 issue: 9 year: 2014 end-page: 1589 ident: CR126 article-title: Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer a phase II study publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0000000000000286 – volume: 13 start-page: 3899 issue: 13 year: 2007 end-page: 3905 ident: CR131 article-title: Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2769 – ident: CR64 – volume: 3 start-page: 7 year: 2015 ident: CR109 article-title: Immunotherapeutic approaches to ovarian cancer treatment publication-title: J Immunother Cancer doi: 10.1186/s40425-015-0051-7 – volume: 16 start-page: 1 issue: 1 year: 2015 ident: CR98 article-title: Immunotherapy for ovarian cancer publication-title: Curr Treat Options Oncol doi: 10.1007/s11864-014-0317-1 – volume: 70 start-page: 133 year: 2017 end-page: 142 ident: CR50 article-title: Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial publication-title: Eur J Cancer doi: 10.1016/j.ejca.2016.09.036 – volume: 27 start-page: 1013 issue: 6 year: 2016 end-page: 1019 ident: CR81 article-title: Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety publication-title: Ann Oncol doi: 10.1093/annonc/mdw133 – volume: 61 start-page: 31 issue: 1 year: 2011 end-page: 49 ident: CR72 article-title: Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic publication-title: CA Cancer J Clin doi: 10.3322/caac.20095 – volume: 27 start-page: 6 year: 2016 ident: CR26 article-title: Prospective phase II trial of trabectedin in BRCAmutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial publication-title: Ann Oncol doi: 10.1093/annonc/mdv608 – ident: CR37 – volume: 374 start-page: 738 issue: 8 year: 2016 end-page: 748 ident: CR18 article-title: Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1505067 – volume: 374 start-page: 1331 issue: 9698 year: 2009 end-page: 1338 ident: CR16 article-title: Dose-dense paclitaxel once a week in combination with carboplatin every 3weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(09)61157-0 – year: 2017 ident: CR91 publication-title: ESMO 2017 press release: rucaparib boosts progression-free survival in BRCA mutant recurrent ovarian cancer – volume: 127 start-page: 2209 issue: 9 year: 2010 end-page: 2221 ident: CR127 article-title: The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial publication-title: Int J Cancer doi: 10.1002/ijc.25423 – volume: 35 start-page: 12 issue: 1 year: 2017 ident: CR95 article-title: Olaparib for maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy: an evidence review group perspective of a NICE single technology appraisal publication-title: PharmacoEconomics doi: 10.1007/s40273-016-0440-x – volume: 119 start-page: 421 year: 2013 end-page: 475 ident: CR117 article-title: Therapeutic cancer vaccines: past, present, and future publication-title: Adv Cancer Res doi: 10.1016/B978-0-12-407190-2.00007-1 – volume: 48 start-page: 2361 issue: 15 year: 2012 end-page: 2368 ident: CR25 article-title: Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis publication-title: Eur J Cancer doi: 10.1016/j.ejca.2012.04.001 – volume: 9 start-page: 1181 year: 2016 end-page: 1188 ident: CR101 article-title: Profile of farletuzumab and its potential in the treatment of solid tumors publication-title: Oncotargets Ther doi: 10.2147/OTT.S98242 – volume: 69 start-page: 617 issue: 6 year: 2010 end-page: 625 ident: CR124 article-title: Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2010.03635.x – ident: CR104 – volume: 348 start-page: 203 issue: 3 year: 2003 end-page: 213 ident: CR107 article-title: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa020177 – volume: 123 start-page: 27 issue: 1 year: 2011 end-page: 32 ident: CR130 article-title: Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2011.06.004 – year: 2016 ident: CR74 article-title: Predictors and modulators of synthetic lethality: an update on PARP inhibitors and personalized medicine publication-title: Biomed Res Int – volume: 27 start-page: 288-+ issue: 4 year: 2013 ident: CR12 article-title: Recurrent epithelial ovarian cancer: an update on treatment publication-title: Oncol N Y – volume: 133 start-page: 362 issue: 2 year: 2014 end-page: 369 ident: CR77 article-title: PARP inhibitors in ovarian cancer: current status and future promise publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2014.02.039 – volume: 60 start-page: 49 year: 2016 end-page: 58 ident: CR93 article-title: Homologous recombination deficiency and ovarian cancer publication-title: Eur J Cancer doi: 10.1016/j.ejca.2016.03.005 – volume: 12 start-page: 5503 issue: 18 year: 2006 end-page: 5510 ident: CR116 article-title: Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-2670 – volume: 7 start-page: 52553 issue: 32 year: 2016 end-page: 52574 ident: CR97 article-title: Targeting folate receptor alpha for cancer treatment publication-title: Oncotarget doi: 10.18632/oncotarget.9651 – year: 2016 ident: CR67 article-title: The CHIVA study: a GINECO randomized double blind phase II trial of nintedanib versus placebo with the neo-adjuvant chemotherapy (NACT) strategy for patients (pts) with advanced unresectable ovarian cancer (OC). Report of the interval debulking surgery (IDS) safety outcome publication-title: Ann Oncol – volume: 17 start-page: 1568 issue: 10 year: 2006 end-page: 1577 ident: CR115 article-title: The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR publication-title: Ann Oncol doi: 10.1093/annonc/mdl357 – volume: 23 start-page: 373 issue: 11 year: 2016 end-page: 381 ident: CR123 article-title: Intraperitoneal immunotherapy: historical perspectives and modern therapy publication-title: Cancer Gene Ther doi: 10.1038/cgt.2016.49 – volume: 25 start-page: 846 issue: 6 year: 2014 end-page: 859 ident: CR53 article-title: Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.05.016 – ident: CR31 – volume: 4 start-page: 6 year: 2014 ident: CR5 article-title: Gene expression analysis in ovarian cancer—faults and hints from DNA microarray study publication-title: Front Oncol doi: 10.3389/fonc.2014.00006 – volume: 16 start-page: 928 issue: 8 year: 2015 end-page: 936 ident: CR44 article-title: Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00086-8 – ident: CR76 – volume: 42 start-page: 918 issue: 7 year: 2011 end-page: 931 ident: CR1 article-title: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm publication-title: Hum Pathol doi: 10.1016/j.humpath.2011.03.003 – volume: 24 start-page: 238 issue: 2 year: 2014 end-page: 246 ident: CR27 article-title: Secondary complete cytoreduction in recurrent ovarian cancer benefit of optimal patient selection using scoring system publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0000000000000051 – volume: 8 start-page: 12389 issue: 7 year: 2017 end-page: 12405 ident: CR40 article-title: Bevacizumab in ovarian cancer: a critical review of phase III studies publication-title: Oncotarget – volume: 45 start-page: 19 year: 2009 ident: CR11 article-title: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 115 start-page: 1157 issue: 10 year: 2016 ident: 3501_CR54 publication-title: Br J Cancer doi: 10.1038/bjc.2016.311 – volume: 8 start-page: 1193 issue: 10 year: 2016 ident: 3501_CR112 publication-title: Immunotherapy doi: 10.2217/imt-2016-0034 – ident: 3501_CR21 doi: 10.1002/14651858.CD005340.pub4 – volume: 387 start-page: 1066 issue: 10023 year: 2016 ident: 3501_CR59 publication-title: Lancet doi: 10.1016/S0140-6736(15)01167-8 – volume: 64 start-page: 7 issue: 6 year: 2014 ident: 3501_CR32 publication-title: Nowotw J Oncol – volume: 102 start-page: 131 issue: 2 year: 2006 ident: 3501_CR45 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2006.06.014 – ident: 3501_CR51 – volume: 348 start-page: 203 issue: 3 year: 2003 ident: 3501_CR107 publication-title: N Engl J Med doi: 10.1056/NEJMoa020177 – volume: 133 start-page: 362 issue: 2 year: 2014 ident: 3501_CR77 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2014.02.039 – ident: 3501_CR94 – volume: 2 start-page: 309 year: 2011 ident: 3501_CR125 publication-title: J Cancer doi: 10.7150/jca.2.309 – year: 2015 ident: 3501_CR84 publication-title: Cancer Res doi: 10.1158/1538-7445.Am2015-Ct324 – volume: 3 start-page: 8 issue: 6 year: 2007 ident: 3501_CR23 publication-title: Onkologia w Praktyce Klinicznej – volume: 7 start-page: 52553 issue: 32 year: 2016 ident: 3501_CR97 publication-title: Oncotarget doi: 10.18632/oncotarget.9651 – volume-title: Advanced (stage III-IV) ovarian cancer surgery. Quality indicators. Complete report year: 2015 ident: 3501_CR10 – volume: 60 start-page: 49 year: 2016 ident: 3501_CR93 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2016.03.005 – volume: 374 start-page: 738 issue: 8 year: 2016 ident: 3501_CR18 publication-title: N Engl J Med doi: 10.1056/NEJMoa1505067 – ident: 3501_CR31 – volume: 8 start-page: 12389 issue: 7 year: 2017 ident: 3501_CR40 publication-title: Oncotarget doi: 10.18632/oncotarget.13310 – volume: 30 start-page: 362 issue: 4 year: 2012 ident: 3501_CR70 publication-title: J Clin Oncol doi: 10.1200/Jco.2010.34.3178 – volume: 11 start-page: 11 issue: 5 year: 2015 ident: 3501_CR6 publication-title: Oncol Clin Pract – volume: 21 start-page: 771 issue: 4 year: 2011 ident: 3501_CR14 publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0b013e31821bb8aa – year: 2016 ident: 3501_CR74 publication-title: Biomed Res Int doi: 10.1155/2016/2346585 – volume: 45 start-page: 19 year: 2009 ident: 3501_CR11 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 119 start-page: 421 year: 2013 ident: 3501_CR117 publication-title: Adv Cancer Res doi: 10.1016/B978-0-12-407190-2.00007-1 – ident: 3501_CR76 – volume: 124 start-page: 1 issue: 1 year: 2014 ident: 3501_CR8 publication-title: Int J Gynaecol Obstet doi: 10.1016/j.ijgo.2013.10.001 – volume: 4 start-page: 6 year: 2014 ident: 3501_CR5 publication-title: Front Oncol doi: 10.3389/fonc.2014.00006 – volume: 16 start-page: 87 issue: 1 year: 2015 ident: 3501_CR82 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71135-0 – volume: 374 start-page: 1331 issue: 9698 year: 2009 ident: 3501_CR16 publication-title: Lancet doi: 10.1016/S0140-6736(09)61157-0 – volume: 8 start-page: 3691 year: 2015 ident: 3501_CR63 publication-title: Oncotargets Ther doi: 10.2147/Ott.S78805 – ident: 3501_CR38 – volume: 35 start-page: 12 issue: 1 year: 2017 ident: 3501_CR95 publication-title: PharmacoEconomics doi: 10.1007/s40273-016-0440-x – volume: 102 start-page: 433 issue: 5 year: 2016 ident: 3501_CR78 publication-title: Tumori doi: 10.5301/tj.5000558 – year: 2013 ident: 3501_CR66 publication-title: Oncotargets Ther doi: 10.2147/Ott.S30238 – ident: 3501_CR19 – ident: 3501_CR30 – volume: 141 start-page: 208 year: 2016 ident: 3501_CR22 publication-title: Gynecol Oncol – volume: 25 start-page: 1405 issue: 12 year: 2016 ident: 3501_CR100 publication-title: Expert Opin Investig Drugs doi: 10.1080/13543784.2016.1254616 – volume: 125 start-page: 42 issue: 1 year: 2012 ident: 3501_CR134 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2011.11.021 – volume: 24 start-page: 1583 issue: 9 year: 2014 ident: 3501_CR126 publication-title: Int J Gynecol Cancer doi: 10.1097/Igc.0000000000000286 – volume: 24 start-page: 238 issue: 2 year: 2014 ident: 3501_CR27 publication-title: Int J Gynecol Cancer doi: 10.1097/Igc.0000000000000051 – volume: 15 start-page: 799 issue: 8 year: 2014 ident: 3501_CR71 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70244-X – year: 2017 ident: 3501_CR96 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.35.15_suppl.5516 – volume: 49 start-page: 3191 issue: 15 year: 2013 ident: 3501_CR20 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2013.06.013 – volume: 115 start-page: 1234 issue: 6 year: 2009 ident: 3501_CR9 publication-title: Cancer doi: 10.1002/cncr.24149 – volume: 129 start-page: 452 issue: 3 year: 2013 ident: 3501_CR102 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2013.03.002 – volume: 19 start-page: 7 year: 2012 ident: 3501_CR35 publication-title: Ann Surg Oncol doi: 10.1245/s10434-012-2510-4 – volume: 27 start-page: 114 issue: 1 year: 2016 ident: 3501_CR41 publication-title: Ann Oncol doi: 10.1093/annonc/mdv500 – volume: 376 start-page: 1155 issue: 9747 year: 2010 ident: 3501_CR13 publication-title: Lancet doi: 10.1016/S0140-6736(10)61268-8 – volume: 27 start-page: 450 issue: 4 year: 2015 ident: 3501_CR114 publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.03.001 – ident: 3501_CR89 – volume-title: EMA approval: avastin autorization details year: 2009 ident: 3501_CR15 – volume: 41 start-page: 48 issue: 1 year: 2017 ident: 3501_CR111 publication-title: Curr Probl Cancer doi: 10.1016/j.currproblcancer.2016.11.003 – volume: 375 start-page: 2154 issue: 22 year: 2016 ident: 3501_CR87 publication-title: N Engl J Med doi: 10.1056/NEJMoa1611310 – volume: 17 start-page: 1568 issue: 10 year: 2006 ident: 3501_CR115 publication-title: Ann Oncol doi: 10.1093/annonc/mdl357 – volume: 24 start-page: 26 year: 2017 ident: 3501_CR113 publication-title: J Biomed Sci doi: 10.1186/s12929-017-0329-9 – volume: 4 start-page: 34 year: 2016 ident: 3501_CR118 publication-title: J Immunother Cancer doi: 10.1186/s40425-016-0137-x – ident: 3501_CR64 – volume: 16 start-page: 1 issue: 1 year: 2015 ident: 3501_CR98 publication-title: Curr Treat Options Oncol doi: 10.1007/s11864-014-0317-1 – ident: 3501_CR104 – volume: 70 start-page: 133 year: 2017 ident: 3501_CR50 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2016.09.036 – volume: 145 start-page: 220 year: 2017 ident: 3501_CR80 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2017.03.505 – volume: 2012 start-page: 682480 year: 2012 ident: 3501_CR135 publication-title: J Oncol doi: 10.1155/2012/682480 – volume: 4 start-page: 118 issue: 1 year: 2015 ident: 3501_CR99 publication-title: Transl Cancer Res doi: 10.3978/j.issn.2218-676X.2015.01.04 – volume: 34 start-page: 41 issue: 1 year: 2015 ident: 3501_CR105 publication-title: Cancer Metastasis Rev doi: 10.1007/s10555-014-9539-8 – volume: 3 start-page: 14 issue: 11 year: 2016 ident: 3501_CR110 publication-title: Gynecol Oncol Res Pract – volume: 10 start-page: 973 year: 2017 ident: 3501_CR49 publication-title: Oncotargets Ther doi: 10.2147/Ott.S119879 – volume: 7 start-page: 188 issue: 2 year: 2016 ident: 3501_CR33 publication-title: India J Surg Oncol doi: 10.1007/s13193-016-0501-9 – volume: 26 start-page: 2034 issue: 10 year: 2015 ident: 3501_CR103 publication-title: Ann Oncol doi: 10.1093/annonc/mdv250 – volume: 365 start-page: 2473 issue: 26 year: 2011 ident: 3501_CR42 publication-title: N Engl J Med doi: 10.1056/NEJMoa1104390 – ident: 3501_CR75 – ident: 3501_CR69 – volume: 23 start-page: 373 issue: 11 year: 2016 ident: 3501_CR123 publication-title: Cancer Gene Ther doi: 10.1038/cgt.2016.49 – volume: 316 start-page: 10 year: 2017 ident: 3501_CR52 publication-title: Cell Immunol doi: 10.1016/j.cellimm.2017.04.005 – volume: 15 start-page: 852 issue: 8 year: 2014 ident: 3501_CR79 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70228-1 – volume: 123 start-page: 27 issue: 1 year: 2011 ident: 3501_CR130 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2011.06.004 – volume: 17 start-page: 78 issue: 1 year: 2016 ident: 3501_CR65 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00366-6 – volume: 102 start-page: 18538 issue: 51 year: 2005 ident: 3501_CR108 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0509182102 – volume: 7 start-page: 28059 issue: 19 year: 2016 ident: 3501_CR132 publication-title: Oncotarget doi: 10.18632/oncotarget.8574 – volume: 14 start-page: 267 year: 2016 ident: 3501_CR92 publication-title: J Transl Med doi: 10.1186/s12967-016-1027-1 – volume: 8 start-page: 1179 issue: 9 year: 2012 ident: 3501_CR121 publication-title: Hum Vaccin Immunother doi: 10.4161/hv.20738 – volume: 27 start-page: 288-+ issue: 4 year: 2013 ident: 3501_CR12 publication-title: Oncol N Y – volume: 139 start-page: 10 issue: 1 year: 2015 ident: 3501_CR47 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2015.08.004 – volume: 16 start-page: 928 issue: 8 year: 2015 ident: 3501_CR44 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00086-8 – volume: 18 start-page: 75 issue: 1 year: 2017 ident: 3501_CR90 publication-title: Lancet Oncol doi: 10.1016/s1470-2045(16)30559-9 – volume: 34 start-page: 41 issue: 1 year: 2015 ident: 3501_CR24 publication-title: Chin J Cancer doi: 10.5732/cjc.014.10278 – volume: 32 start-page: 3374 issue: 30 year: 2014 ident: 3501_CR61 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.55.7348 – volume: 142 start-page: 1239 issue: 6 year: 2016 ident: 3501_CR4 publication-title: J Cancer Res Clin doi: 10.1007/s00432-016-2147-y – volume: 16 start-page: 561 issue: 5 year: 2015 ident: 3501_CR60 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)70115-4 – volume: 13 start-page: 3899 issue: 13 year: 2007 ident: 3501_CR131 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2769 – volume: 365 start-page: 2484 issue: 26 year: 2011 ident: 3501_CR43 publication-title: N Engl J Med doi: 10.1056/NEJMoa1103799 – volume: 3 start-page: 7 year: 2015 ident: 3501_CR109 publication-title: J Immunother Cancer doi: 10.1186/s40425-015-0051-7 – volume: 7 start-page: 7 issue: 11 year: 2015 ident: 3501_CR48 publication-title: Oncotarget – volume: 42 start-page: 918 issue: 7 year: 2011 ident: 3501_CR1 publication-title: Hum Pathol doi: 10.1016/j.humpath.2011.03.003 – volume: 18 start-page: 5449 issue: 19 year: 2012 ident: 3501_CR119 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.Ccr-12-1116 – volume: 136 start-page: 37 issue: 1 year: 2015 ident: 3501_CR62 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2014.11.074 – volume-title: ESMO 2017 press release: rucaparib boosts progression-free survival in BRCA mutant recurrent ovarian cancer year: 2017 ident: 3501_CR91 – volume: 69 start-page: 617 issue: 6 year: 2010 ident: 3501_CR124 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2010.03635.x – volume: 27 start-page: 6 year: 2016 ident: 3501_CR26 publication-title: Ann Oncol doi: 10.1093/annonc/mdv608 – volume: 11 start-page: 9 issue: 1 year: 2013 ident: 3501_CR34 publication-title: Curr Gynecol Oncol doi: 10.15557/CGO.2013.0003 – volume: 19 start-page: 431 issue: 4 year: 2016 ident: 3501_CR57 publication-title: Value Health doi: 10.1016/j.jval.2016.01.013 – volume: 15 start-page: 1207 issue: 11 year: 2014 ident: 3501_CR83 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70391-2 – volume: 14 start-page: 1020 issue: 10 year: 2013 ident: 3501_CR17 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70363-2 – volume: 31 start-page: 1554 issue: 12 year: 2013 ident: 3501_CR120 publication-title: J Clin Oncol doi: 10.1200/Jco.2012.46.4057 – volume: 34 start-page: 1553 issue: 4 year: 2014 ident: 3501_CR122 publication-title: Anticancer Res – volume: 25 start-page: 846 issue: 6 year: 2014 ident: 3501_CR53 publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.05.016 – volume: 48 start-page: 2361 issue: 15 year: 2012 ident: 3501_CR25 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2012.04.001 – volume: 196 start-page: 245 issue: 3 year: 2007 ident: 3501_CR3 publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2006.10.874 – volume: 26 start-page: 605 issue: 5 year: 2014 ident: 3501_CR36 publication-title: Cancer Cell doi: 10.1016/j.ccell.2014.10.006 – volume: 77 start-page: 1029 issue: 9 year: 2017 ident: 3501_CR86 publication-title: Drugs doi: 10.1007/s40265-017-0752-y – volume: 7 start-page: 57 year: 2014 ident: 3501_CR39 publication-title: J Ovarian Res doi: 10.1186/1757-2215-7-57 – volume: 32 start-page: 1302 issue: 13 year: 2014 ident: 3501_CR46 publication-title: J Clin Oncol doi: 10.1200/JCO.2013.51.4489 – volume: 4 start-page: 28 issue: 2 year: 2016 ident: 3501_CR106 publication-title: Biomedicines – volume: 77 start-page: 585 issue: 5 year: 2017 ident: 3501_CR88 publication-title: Drugs doi: 10.1007/s40265-017-0716-2 – volume: 69 start-page: 1275 year: 2015 ident: 3501_CR2 publication-title: Postep Hig Med Dosw doi: 10.5604/17322693.1184451 – volume: 19 start-page: 523 issue: 5 year: 2014 ident: 3501_CR55 publication-title: Oncologist doi: 10.1634/theoncologist.2013-0322 – volume: 105 start-page: 884 issue: 7 year: 2011 ident: 3501_CR58 publication-title: Brit J Cancer doi: 10.1038/bjc.2011.334 – ident: 3501_CR37 – volume: 66 start-page: 13 year: 2012 ident: 3501_CR73 publication-title: Postepy Hig Med Dosw doi: 10.5604/17322693.1000548 – year: 2016 ident: 3501_CR67 publication-title: Ann Oncol doi: 10.1093/annonc/mdw374.6 – year: 2015 ident: 3501_CR85 publication-title: Cancer Res doi: 10.1158/1538-7445.Am2015-Ct323 – volume: 61 start-page: 31 issue: 1 year: 2011 ident: 3501_CR72 publication-title: CA Cancer J Clin doi: 10.3322/caac.20095 – volume: 127 start-page: 2209 issue: 9 year: 2010 ident: 3501_CR127 publication-title: Int J Cancer doi: 10.1002/ijc.25423 – volume: 28 start-page: 1 issue: 5 year: 2017 ident: 3501_CR29 publication-title: J Gynecol Oncol doi: 10.3802/jgo.2017.28.e74 – volume: 6 start-page: 25017 issue: 28 year: 2015 ident: 3501_CR128 publication-title: Oncotarget doi: 10.18632/oncotarget.4496 – volume: 23 start-page: E461 issue: 5 year: 2016 ident: 3501_CR56 publication-title: Curr Oncol doi: 10.3747/co.23.3139 – volume: 12 start-page: 5503 issue: 18 year: 2006 ident: 3501_CR116 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-2670 – volume: 21 start-page: 289 issue: 2 year: 2011 ident: 3501_CR28 publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0b013e31820aaafd – volume: 13 start-page: 154 issue: 2 year: 2012 ident: 3501_CR133 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70338-2 – ident: 3501_CR68 – volume: 138 start-page: 343 issue: 2 year: 2015 ident: 3501_CR129 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2015.06.003 – volume: 9 start-page: 1181 year: 2016 ident: 3501_CR101 publication-title: Oncotargets Ther doi: 10.2147/Ott.S98242 – volume: 4 start-page: 287 year: 2009 ident: 3501_CR7 publication-title: Annu Rev Pathol Mech Dis doi: 10.1146/annurev.pathol.4.110807.092246 – volume: 27 start-page: 1013 issue: 6 year: 2016 ident: 3501_CR81 publication-title: Ann Oncol doi: 10.1093/annonc/mdw133 |
| SSID | ssj0004133 |
| Score | 2.6561675 |
| SecondaryResourceType | review_article |
| Snippet | Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 17 |
| SubjectTerms | Angiogenesis Cancer Research Cancer therapies cancer therapy Chemotherapy chronic diseases Chronic illnesses Clinical trials cost effectiveness Drug development drug therapy epithelium folate receptors Folic acid immunotherapy Medicine Medicine & Public Health Oncology Ovarian cancer ovarian neoplasms Pharmacology/Toxicology Poly(ADP-ribose) polymerase Review Review Article Ribose Surgery |
| SummonAdditionalLinks | – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZT8MwDLZgIMQL91EuFYR4gEVKabKkjwiBeAFNXOKtalNPTEIdWsek_XucXmNcErxVjdumrh3bdfwZ4DCJE50kUjJh0GcCuWKBT0dkHU61TqxNjPNmE-rmRj89Be2yjjurdrtXKcl8pa6L3fIsILOrqk2GMT0NM2TttNXG27vHcTGkV_SP94VgUnFRpTK_u8WkMfriYX7dKPkpW5obocvFf01_CRZKn9M9K4RkGaYwXYG56zKrvgJH7QK_etR078flWFnTPXLbY2Tr0SocnBU7BjK3m7q9IYXZUeoae6bvFoVcozV4uLy4P79iZZMFZiT3B8zrKGuwIoVkuck4IS2BLakSLjEQOkrQoueoFsZGdESEAQVc2DEtRX6CF0Wk3evQSHspbgI9z2DiIRqtAyGUr7noKCliJB8EPR47wCtuh6ZEILeNMF7CGjs5Z1JITAotk0LtwHF9yWsBv_Eb8U71CcNSE7PQIweXvDQZ-A7s18OkQzYxEqXYe8tpaGGzOcmfaWi8Re9B4ZgDG4VU1DM6tUEs9wMH1IS81AQWw3tyJO0-51je0gIQetyBk0pqPkz9pxfd-hP1NsyTl6eL_0Y70Bj033AXZs1w0M36e7nyvAOikhE_ priority: 102 providerName: Springer Nature |
| Title | Advances in ovarian cancer therapy |
| URI | https://link.springer.com/article/10.1007/s00280-017-3501-8 https://www.ncbi.nlm.nih.gov/pubmed/29249039 https://www.proquest.com/docview/1977617593 https://www.proquest.com/docview/1978320768 https://www.proquest.com/docview/3206222182 https://pubmed.ncbi.nlm.nih.gov/PMC5754410 |
| Volume | 81 |
| WOSCitedRecordID | wos000419437500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1432-0843 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004133 issn: 0344-5704 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dT9swED-NghAvY-NrAYayCfGwNcJp7Np5QgyB9rKq4kt9ixL7KiqhlDUFqf_9zomTUhC87MVKYkfx5Xy-O5_9O4BDkxlljBAB1xgFHJkM4oiuSDt0lDJWJ2ZlsgnZ66nBIO67BbfCbaus58RyojZjbdfIj0MyVEjbijg6efgb2KxRNrrqUmgswbJFKuMtWP513utfzk9GhlUy-YjzQEjG67gmK2FEO8puyiIhE-RTq0XN9MrcfL1r8kXotNRIF-v_S8sn-OhsUf-0Gjyf4QPmG7D6x0XbN-CoX-Faz9r-9fyYVtH2j_z-HPF6tgnfT6udBIU_yv3xE7nfae5r-2TiVwe8Zltwc3F-ffY7cMkXAi1YNA3CobSKLJVIGp2UFtLU2BXSMIExV6lBi6oju5hpPuQpxuSI4VB3JdkPYZqS1G9DKx_n-AXoexpNiKiVijmXkWJ8KAXPkGwTDFnmAat_fKIdMrlNkHGfNJjKJa8S4lVieZUoD340rzxUsBzvNd6v2ZA4CS2SOQ88-NZUk2zZgEma4_ixbEMTno1Vvt2G6rtEB7lpHuxUA6TpUcc6tyyKPZALQ6dpYLG9F2vy0V2J8S0sMGHIPPhZD7JnXX-L0N33Cd2DNTL3VLWAtA-t6eQRv8KKfpqOiskBLMmBLEtFpToLD5ww0d3l1e0_SdchIA |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB5VBUEvPMorUMAg6AEa4ST22jkgVBWqVm1Xe1ik3tLEmVVXQtmy2Rbtn-I3MpPXslTtrQduUewomXienvE3AO_yLLd5rrWvHEa-Qmn8OKIrsg6htTnbxKxqNmH6fXt8HA9W4Hd7FobLKludWCnqfOJ4j_xTQI4KWVsdR1_OfvrcNYqzq20LjZotDnD-i0K28vP-V1rf92G4-224s-c3XQV8p2U084ORYQ2dGiRTRdoYSeZ72uRSY6xsmiPDxZgeZk6NVIoxRRg4cj1DhjFIU8PgS6TybzGSHQd7dmdRUkIGoW7HrJSvjVRtFlVWoKWh5RIwEmlNEbxdtoOXnNvLNZr_JGor-7d7_3_7cw_gXuNpi-1aNB7CChbrcOeoqSVYh81Bjdo93xLDxSG0cktsisECz3v-CN5u13USpRgXYnKRksgWwvGdqaiPr80fw_cbIeUJrBaTAp8Bvc9hHiA6a2OlTGSlGhmtMiTPCwOZeSDbhU5cg7vO7T9-JB1idMUbCfFGwryRWA8-dI-c1aAj103eaJc9afRPmSzW3IM33TBpDk4HpQVOzqs5pM45E3v1HBrvER0UhHrwtGbI7otCDt1lFHtglli1m8DI5csjxfi0QjDXDLsYSA8-tkz916dfRejz6wl9DXf3hkeHyeF-_-AFrJFja-utsg1YnU3P8SXcdhezcTl9VQmtgJOb5vU_Hyd2rg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB5VBVVceJRXoIBB0AM0qpPYa-eAUNWyoiqs9lCk3kJiT8RKKFs226L9a_w6xnGSZanaWw_cVrGjjeNvXpnxNwCvbWG1tVKGwmASCuQqTBP6RdYh1to6m1g0zSbUaKRPTtLxGvzuzsK4sspOJzaK2k6N-0a-G5GjQtZWpslu2ZZFjA-GH05_hq6DlMu0du00PESOcPGLwrf6_eEB7fWbOB5-PN7_FLYdBkIjeTIPo1I5bZ0rJLNFmhlJ_gdSWS4xFTq36Khj1AALI0qRY0rRBpZmoMhIRnmuHBETqf8bKiEUu1Pq-8vyEjIOvjWzEKFUXHQZVd4QmMbalYOReEuK5vWqTbzg6F6s1_wnadvYwuGd__kt3oXbrQfO9rzI3IM1rDZh40tbY7AJ22PP5r3YYcfLw2n1Dttm4yXP9-I-vNrz9RM1m1Rsep6TKFfMuCsz5o-1LR7A12tZykNYr6YVPgb6P4M2QjRap0KoRHNRKikKJI8MI14EwLtNz0zLx-7agvzIeibpBicZ4SRzOMl0AG_7W049GclVk7c6CGStXqqz5f4H8LIfJo3i0kR5hdOzZg6peZehvXwOjQ9oHRScBvDIg7N_otiF9DxJA1ArsO0nOEbz1ZFq8r1hNpeOjjHiAbzrAP7Xo1-20CdXL_QFbBDEs8-Ho6OncIv8Xe2_oG3B-nx2hs_gpjmfT-rZ80Z-GXy7bqj_AZJFf3M |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Advances+in+ovarian+cancer+therapy&rft.jtitle=Cancer+chemotherapy+and+pharmacology&rft.au=Cortez%2C+Alexander+J&rft.au=Tudrej%2C+Patrycja&rft.au=Kujawa%2C+Katarzyna+A&rft.au=Lisowska%2C+Katarzyna+M&rft.date=2018-01-01&rft.issn=1432-0843&rft.eissn=1432-0843&rft.volume=81&rft.issue=1&rft.spage=17&rft_id=info:doi/10.1007%2Fs00280-017-3501-8&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-5704&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-5704&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-5704&client=summon |